Peking University Cancer Hospital & Institute: clinical-trial pipeline
Peking University Cancer Hospital & Institute is the sponsor of 265 clinical trials in ClinicalTrials.gov and the EU CTIS portal; 116 are not yet finished and 9 were first posted in the last 90 days. Source: Arcadium Data, data as of .
Open trials116
Phase 2/3 and 311
Countries1
New in 90 days9
Trials by phase
| Phase | Trials |
|---|---|
| Not applicable | 126 |
| Phase 2 | 93 |
| Phase 1 | 16 |
| Phase 1/2 | 9 |
| Early phase 1 | 7 |
| Phase 3 | 7 |
| Phase 2/3 | 4 |
| Phase 4 | 3 |
Trials by status
| Status | Trials |
|---|---|
| Unknown | 114 |
| Not yet recruiting | 62 |
| Recruiting | 51 |
| Completed | 34 |
| Active, not recruiting | 3 |
| Terminated | 1 |
Condition areas
| Area | Trials |
|---|---|
| Oncology | 249 |
| Gastroenterology and liver | 37 |
| Nephrology and urology | 13 |
| Cardiovascular | 6 |
| Metabolic and endocrine (diabetes, obesity) | 4 |
| Women's health and obstetrics | 4 |
| Dermatology | 2 |
| Infectious disease and vaccines | 2 |
| Rare and genetic diseases | 2 |
| Haematology | 1 |
| Immunology and rheumatology | 1 |
| Respiratory | 1 |
Countries
| Country | Trials |
|---|---|
| China | 213 |
Latest changes
| Day | Change | Trial |
|---|---|---|
| 2026-10-20 | New trial posted | SBRT Combined With Iparomlimab and Tuvonralimab (QL1706) and Bevacizumab for Hepatocellul… |
| 2026-10-02 | New trial posted | A Study of QL1706 Combined With OH2 Injection in Perioperative Treatment of Stage III Res… |
| 2026-09-29 | New trial posted | Clinical Investigator-Initiated Trial (IIT) of PD-L1-Targeted Radionuclide Probes |
| 2026-09-28 | New trial posted | Trastuzumab Rezetecan Plus Bevacizumab in Platinum-Sensitive Recurrent Ovarian Cancer |
| 2026-09-22 | New trial posted | Local Methylene Blue Injection for Prevention of Anastomotic Leakage and Permanent Stoma… |
| 2026-09-16 | New trial posted | Risk of Esophageal Cancer Returning After Immunotherapy, Chemotherapy, and Surgery |
| 2026-09-11 | New trial posted | Retlirafusp Alfa Plus Targeted Therapy and Chemotherapy for Unresectable Colorectal Liver… |
| 2026-08-28 | New trial posted | SLNB Combined With WLNB for Axillary De-escalation in Breast Cancer Patients With Abnorma… |
| 2026-08-27 | New trial posted | 89Zr-DFO-Mirvetuximab PET/CT Imaging for Companion Diagnosis and Response Evaluation in O… |
Open trials
The 25 most recently changed open trials.
| Registry id | Title | Phase | Status | Countries |
|---|---|---|---|---|
| NCT07692555 | Development and Validation of a Colorectal Cancer Diagnostic Model | Not applicable | Not yet recruiting | China |
| NCT07165418 | A Comparison of Vorolanib Tablets Combined With Everolimus Versus Sunitinib in Patients With Advanced Renal C… | Phase 3 | Not yet recruiting | China |
| NCT06424626 | A Trial of AK104 or AK112 in Combination With Axitinib in Patients With Metastatic Mucosal Melanoma | Phase 1 | Recruiting | China |
| NCT07007728 | Iparomlimab/Tuvonralimab Combined With Bevacizumab and CAPEOX as Conversion Therapy for Colorectal Cancer Liv… | Phase 2 | Not yet recruiting | China |
| NCT05789043 | Camrelizumab in Combination With Apatinib and Temozolomide as First-line Treatment in Advanced Acral Melanoma | Phase 3 | Recruiting | China |
| NCT06641674 | EGFR Mutation Targeting Molecular Probe for PET Imaging | Not applicable | Not yet recruiting | China |
| NCT07383285 | CAPOX and Bevacizumab With or Without Primary Tumor Radiotherapy and Iparomlimab and Tuvonralimab as First-li… | Phase 2 | Not yet recruiting | |
| NCT06757387 | Chidamide Plus Golidocitinib in Relapsed/Refractory Peripheral T-Cell Lymphoma | Phase 1/2 | Not yet recruiting | |
| NCT06869239 | Prediction of Response to PD-L1 Inhibitor After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer Usi… | Not applicable | Recruiting | China |
| NCT06869213 | A Single-arm, Open, Single-center Exploratory Study of Adebrelimab (SHR-1316) in Combination With Chemotherap… | Phase 2 | Recruiting | China |
| NCT04622566 | Lenvatinib and Pembrolizumab in Resectable Mucosal Melanoma | Phase 2 | Not yet recruiting | China |
| NCT06992362 | Perioperative Treatment of Hepatoid Adenocarcinoma of Stomach | Phase 2 | Recruiting | China |
| NCT06099821 | KN046 Plus Regorafenib or Apatinib in MSI-H Digestive System Cancers Resistant to PD-1/PD-L1 Blockade | Phase 2 | Active, not recruiting | China |
| NCT06926179 | Safety, Efficacy, and Survival Outcomes of Neoadjuvant/Induction Immunotherapy in Surgical and Radiotherapeut… | Not applicable | Recruiting | China |
| NCT05104788 | A Study of Icotinib With Chemotherapy as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-… | Phase 2 | Recruiting | China |
| NCT07470203 | Pyrotinib Combined With Trastuzumab and Pertuzumab for Maintenance Therapy in HER2-Positive Advanced Breast C… | Not applicable | Not yet recruiting | |
| NCT07381543 | Adebrelimab Maintenance Therapy for LS-SCLC Post Induction Chemo-Adebrelimab Plus CRT or CRT Alone | Phase 2 | Not yet recruiting | China |
| NCT06674252 | A Study on the Improvement of Postoperative Symptoms and Survival Benefits of Modified Bufei Decoction in Eld… | Not applicable | Recruiting | China |
| NCT05512481 | Camrelizumab Plus Apatinib and Temozolomide as Neoadjuvant in High Risk Acral Melanoma | Phase 2 | Recruiting | China |
| NCT06784206 | Adebrelimab Maintenance Therapy After Concurrent Chemoradiotherapy with Hyperfractionated Radiotherapy in Lim… | Phase 2 | Not yet recruiting | China |
| NCT07413042 | A Phase I Study to Evaluate the Safety and Preliminary Efficacy of [225Ac]Ac-DOTATATE Injection Combined With… | Phase 1 | Recruiting | China |
| NCT07251868 | Evaluation of Trop-2 ADC in Breast Cancer Patients With Brain Metastases: A Real-World Study | Not applicable | Recruiting | China |
| NCT07344974 | Hand and Foot Bath for Taxane-Induced Peripheral Neurotoxicity | Phase 4 | Not yet recruiting | |
| NCT07004712 | Efficacy and Biomarkers of the Second-line Treatment of Adebelizumab Combined With Irinotecan Liposome in Adv… | Phase 2 | Not yet recruiting | China |
| NCT07417241 | SHR-A1811 vs Pyrotinib/Capecitabine in Trastuzumab-Resistant HER2+ Advanced Breast Cancer: A Randomized Study | Phase 2 | Not yet recruiting |
All sponsors: clinical-trial pipeline by sponsor.
Track a sponsor's pipeline
The API returns the same trials by sponsor website, phase, status, condition and country with a change feed, joined to hiring and public contract awards. Try it without a key on one sponsor.
Sources: ClinicalTrials.gov (U.S. National Library of Medicine, public domain) and the EU Clinical Trials Information System public portal (European Medicines Agency), data as of 2026-10-25. A trial that one register cites in the other is shown once. Organisation-level data only: investigators, contact persons and site names are not stored, and a sponsor that could be a private person is withheld. Sponsor-to-website matches are made by name and can be wrong; check the register before relying on a record. Independent of the NLM, NIH and EMA.
Cite as: Arcadium Data, "Peking University Cancer Hospital & Institute clinical trials: 116 open, 11 in phase 3", https://arcadiumdata.io/clinical-trials/sponsor/peking-university-cancer-hospital-institute/, data as of 2026-10-25.